Shares of Inogen, Inc (NASDAQ:INGN) shot up 1.3% during mid-day trading on Thursday after Zacks Investment Research upgraded the stock from a hold rating to a buy rating. Zacks Investment Research now has a $131.00 price target on the stock. Inogen traded as high as $124.90 and last traded at $118.90. 208,954 shares were traded during trading, an increase of 63% from the average session volume of 127,924 shares. The stock had previously closed at $117.38.

According to Zacks, “Over the last six months, Inogen has outperformed the broader industry in terms of price. The company expects direct-to-consumer sales to be its fastest growing channel, followed by domestic business-to-business sales in the coming quarters, with solid focus in Europe. Inogen recently signed a lease for its expansion site in Ohio to accelerate growth in domestic direct-to-consumer sales channel. The company took a series of strategic initiatives to strengthen its product offerings and market position. On the flip side, declining rental revenues raise concern. Moreover, since the company generates a significant portion of its revenues from the international market, volatile foreign exchange rate will continue to raise concern.Meanwhile, the company reported a stellar third quarter of 2017, beating the Zacks Consensus Estimate for both the counts. Solid domestic and international business-to-business sales drove revenues.”

INGN has been the topic of several other reports. BidaskClub lowered Inogen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Needham & Company LLC reissued a “buy” rating and set a $108.00 target price on shares of Inogen in a report on Friday, September 1st. Leerink Swann reissued an “outperform” rating and set a $120.00 target price (up from $115.00) on shares of Inogen in a report on Wednesday. Finally, Piper Jaffray Companies reissued a “hold” rating and set a $90.00 target price on shares of Inogen in a report on Tuesday, September 12th. Three research analysts have rated the stock with a hold rating, three have given a buy rating and two have issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $103.14.

In related news, EVP Alison Bauerlein sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $94.93, for a total value of $1,423,950.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Raymond Huggenberger sold 14,000 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $91.67, for a total value of $1,283,380.00. Following the completion of the sale, the director now directly owns 7,808 shares in the company, valued at $715,759.36. The disclosure for this sale can be found here. Insiders sold 67,000 shares of company stock worth $6,424,010 over the last ninety days. 5.31% of the stock is currently owned by insiders.

Large investors have recently added to or reduced their stakes in the stock. Schroder Investment Management Group acquired a new stake in Inogen in the second quarter valued at about $132,000. Ameritas Investment Partners Inc. boosted its stake in Inogen by 6.1% in the second quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock valued at $143,000 after buying an additional 86 shares in the last quarter. Sei Investments Co. boosted its stake in Inogen by 38.1% in the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock valued at $153,000 after buying an additional 443 shares in the last quarter. Victory Capital Management Inc. boosted its stake in Inogen by 17.8% in the second quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock valued at $194,000 after buying an additional 307 shares in the last quarter. Finally, Pinebridge Investments L.P. boosted its stake in Inogen by 1.6% in the second quarter. Pinebridge Investments L.P. now owns 2,143 shares of the medical technology company’s stock valued at $204,000 after buying an additional 33 shares in the last quarter.

The firm has a market cap of $2,449.76, a P/E ratio of 95.43, a price-to-earnings-growth ratio of 4.90 and a beta of 0.99.

Inogen (NASDAQ:INGN) last released its quarterly earnings data on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.04. The business had revenue of $69.00 million for the quarter, compared to analyst estimates of $63.55 million. Inogen had a return on equity of 13.37% and a net margin of 11.36%. Inogen’s revenue was up 26.8% compared to the same quarter last year. During the same period last year, the firm posted $0.25 earnings per share. sell-side analysts anticipate that Inogen, Inc will post 1.2 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Inogen, Inc (INGN) Shares Up 1.3% After Analyst Upgrade” was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.dailypolitical.com/2017/11/10/inogen-inc-ingn-shares-up-1-3-after-analyst-upgrade.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.